Samsung Biologics says Plant 4 to be partially operational by end of year

CEO John Rim speaking at the company's 11th Annual General Meeting of Shareholders last Tuesday
Construction of Plant 4 – dubbed Super Plant – will be complete in 2023
Samsung Biologics has said its new “Super Plant” will be partially operational by the end of the year and fully operational by mid-2023, at which time the company is expected to hold the world’s largest biomanufacturing capacity.
Plant 4 is located in the Songdo district of Incheon, South Korea and will boast 256,000 liters total manufacturing capacity once completed, bringing the CDMO’s overall capacity to 620,000 liters. The 238,000-square-meter floorplan makes it the world's largest biopharmaceutical manufacturing facility of its kind.
The company already has a slate of deals lined up for the plant, having secured CMO contracts with three companies for five different products.
Speaking to CPHI Online, CEO John Rim said the new facility would help to meet increasing demand for biologics.
He said: "By utilizing Plant 4, the company aims to meet the increasing demand of manufacturing for large-scale biologics for a wide array of diseases, tailoring the services to the clients’ specific needs.
Having advanced smart plant technologies and flexible scale of capabilities will allow us to provide stable supply for our clients and ultimately contribute to saving the lives of patients".
Rim also addressed Plant 4 progress at last week's 11th Annual General Meeting of Shareholders, where he announced a three-pronged approach to corporate growth.
In an address to shareholders, he said “We are now venturing into the three core pillars of our multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint”.
The company is expected to begin construction on its fifth plant (Plant 5) this year, described by Rim as a “multi modal plant” where “we will offer services beyond the traditional mammalian monoclonal antibodies production”. The plant will also be based in Incheon and is expected to include mRNA vaccine drug substance production capabilities.
Last year the company secured a contract to perform fill-finish manufacturing of Moderna’s COVID-19 vaccine, but Samsung says the mRNA drug substance expansion is unrelated to this deal.
Additionally, the company plans to purchase land for a second Bio Campus with an expected land mass 30% greater than its current campus (Bio Campus I) in Songdo, for the construction of future large scale plants and an Open Innovation Center.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance